These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31269546)

  • 1. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.
    Savarirayan R; Irving M; Bacino CA; Bostwick B; Charrow J; Cormier-Daire V; Le Quan Sang KH; Dickson P; Harmatz P; Phillips J; Owen N; Cherukuri A; Jayaram K; Jeha GS; Larimore K; Chan ML; Huntsman Labed A; Day J; Hoover-Fong J
    N Engl J Med; 2019 Jul; 381(1):25-35. PubMed ID: 31269546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
    Savarirayan R; Tofts L; Irving M; Wilcox W; Bacino CA; Hoover-Fong J; Ullot Font R; Harmatz P; Rutsch F; Bober MB; Polgreen LE; Ginebreda I; Mohnike K; Charrow J; Hoernschemeyer D; Ozono K; Alanay Y; Arundel P; Kagami S; Yasui N; White KK; Saal HM; Leiva-Gea A; Luna-González F; Mochizuki H; Basel D; Porco DM; Jayaram K; Fisheleva E; Huntsman-Labed A; Day J
    Lancet; 2020 Sep; 396(10252):684-692. PubMed ID: 32891212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.
    Chan ML; Qi Y; Larimore K; Cherukuri A; Seid L; Jayaram K; Jeha G; Fisheleva E; Day J; Huntsman-Labed A; Savarirayan R; Irving M; Bacino CA; Hoover-Fong J; Ozono K; Mohnike K; Wilcox WR; Horton WA; Henshaw J
    Clin Pharmacokinet; 2022 Feb; 61(2):263-280. PubMed ID: 34431071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.
    Savarirayan R; Wilcox WR; Harmatz P; Phillips J; Polgreen LE; Tofts L; Ozono K; Arundel P; Irving M; Bacino CA; Basel D; Bober MB; Charrow J; Mochizuki H; Kotani Y; Saal HM; Army C; Jeha G; Qi Y; Han L; Fisheleva E; Huntsman-Labed A; Day J
    Lancet Child Adolesc Health; 2024 Jan; 8(1):40-50. PubMed ID: 37984383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
    Savarirayan R; Tofts L; Irving M; Wilcox WR; Bacino CA; Hoover-Fong J; Font RU; Harmatz P; Rutsch F; Bober MB; Polgreen LE; Ginebreda I; Mohnike K; Charrow J; Hoernschemeyer D; Ozono K; Alanay Y; Arundel P; Kotani Y; Yasui N; White KK; Saal HM; Leiva-Gea A; Luna-González F; Mochizuki H; Basel D; Porco DM; Jayaram K; Fisheleva E; Huntsman-Labed A; Day JRS
    Genet Med; 2021 Dec; 23(12):2443-2447. PubMed ID: 34341520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model.
    Qi Y; Chan ML; Mould DR; Larimore K; Fisheleva E; Cherukuri A; Day J; Savarirayan R; Irving M; Bacino CA; Hoover-Fong J; Ozono K; Mohnike K; Wilcox WR; Bober MB; Henshaw J
    Clin Pharmacokinet; 2024 May; 63(5):707-719. PubMed ID: 38649657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vosoritide: First Approval.
    Duggan S
    Drugs; 2021 Nov; 81(17):2057-2062. PubMed ID: 34694597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery.
    Savarirayan R; Irving M; Maixner W; Thompson D; Offiah AC; Connolly DJ; Raghavan A; Powell J; Kronhardt M; Jeha G; Ghani S; Fisheleva E; Day JR
    Sci Prog; 2021; 104(1):368504211003782. PubMed ID: 33761804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vosoritide treatment for children with hypochondroplasia: a phase 2 trial.
    Dauber A; Zhang A; Kanakatti Shankar R; Boucher K; McCarthy T; Shafaei N; Seaforth R; Castro MG; Dham N; Merchant N
    EClinicalMedicine; 2024 May; 71():102591. PubMed ID: 38813446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of vosoritide in the treatment of achondroplasia.
    Paton DM
    Drugs Today (Barc); 2022 Sep; 58(9):451-456. PubMed ID: 36102905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Literature review and expert opinion on the impact of achondroplasia on medical complications and health-related quality of life and expectations for long-term impact of vosoritide: a modified Delphi study.
    Savarirayan R; Baratela W; Butt T; Cormier-Daire V; Irving M; Miller BS; Mohnike K; Ozono K; Rosenfeld R; Selicorni A; Thompson D; White KK; Wright M; Fredwall SO
    Orphanet J Rare Dis; 2022 Jun; 17(1):224. PubMed ID: 35698202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-acting C-natriuretic peptide for achondroplasia.
    Schneider EL; Carreras CW; Reid R; Ashley GW; Santi DV
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2201067119. PubMed ID: 35858423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia.
    Prickett TCR; Espiner EA; Irving M; Bacino C; Phillips JA; Savarirayan R; Day JRS; Fisheleva E; Larimore K; Chan ML; Jeha GS
    Sci Rep; 2021 Dec; 11(1):24278. PubMed ID: 34930956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.
    Breinholt VM; Rasmussen CE; Mygind PH; Kjelgaard-Hansen M; Faltinger F; Bernhard A; Zettler J; Hersel U
    J Pharmacol Exp Ther; 2019 Sep; 370(3):459-471. PubMed ID: 31235532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice.
    Semler O; Cormier-Daire V; Lausch E; Bober MB; Carroll R; Sousa SB; Deyle D; Faden M; Hartmann G; Huser AJ; Legare JM; Mohnike K; Rohrer TR; Rutsch F; Smith P; Travessa AM; Verardo A; White KK; Wilcox WR; Hoover-Fong J
    Adv Ther; 2024 Jan; 41(1):198-214. PubMed ID: 37882884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parents' Experience of Administering Vosoritide: A Daily Injectable for Children with Achondroplasia.
    NiMhurchadha S; Butler K; Argent R; Palm K; Baujat G; Cormier-Daire V; Mohnike K
    Adv Ther; 2023 May; 40(5):2457-2470. PubMed ID: 37017912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP.
    Breinholt VM; Mygind PH; Christoffersen ED; Zhang Y; Ota S; Will Charlton R; Viuff D
    Br J Clin Pharmacol; 2022 Nov; 88(11):4763-4772. PubMed ID: 35481707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum NT-proCNP levels increased after initiation of GH treatment in patients with achondroplasia/hypochondroplasia.
    Kubota T; Wang W; Miura K; Nakayama H; Yamamoto K; Fujiwara M; Ohata Y; Tachibana M; Kitaoka T; Takakuwa S; Miyoshi Y; Namba N; Ozono K
    Clin Endocrinol (Oxf); 2016 Jun; 84(6):845-50. PubMed ID: 26814021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two Cases of Cardiovascular Adverse Events Following Subcutaneous Vosoritide Injection in Early Infancy.
    Nishioka A; Adachi N; Tanaka H; Oda Y
    Cureus; 2024 May; 16(5):e59695. PubMed ID: 38841012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial.
    Hertel NT; Eklöf O; Ivarsson S; Aronson S; Westphal O; Sipilä I; Kaitila I; Bland J; Veimo D; Müller J; Mohnike K; Neumeyer L; Ritzen M; Hagenäs L
    Acta Paediatr; 2005 Oct; 94(10):1402-10. PubMed ID: 16299871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.